A Multicenter, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523, a Syk Inhibitor, in Adult Subjects With Immune Thrombocytopenia
Latest Information Update: 20 Aug 2024
At a glance
- Drugs Sovleplenib (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors HUTCHMED
Most Recent Events
- 18 Apr 2024 Status changed from not yet recruiting to recruiting.
- 29 Feb 2024 Status changed from planning to not yet recruiting.
- 28 Feb 2024 According to a HUTCHMED media release, company plans to initiate a dose-finding study in ITP in the U.S./EU in mid-2024.